Here are five key trends in the market:
1. The market grew by more than 17 percent in 2014.
2. The aging population is a driver for stem cell therapies, as it is for the orthopedic market in general.
3. Cell-based therapies are generally very costly, and this may hinder the market.
4. NuVasive led the U.S. orthopedic stem cell market in 2014.
5. NuVasive purchased the Osteocel line of products from Osiris Orthopedics in 2008. The purchase was to complement their strong spinal hardware business.
More articles on devices:
Clinical trials, team growth, IPO — 8 key notes on Bone Therapeutics’ 2014
Implanet Q1 revenue drops 21%, Spine up 77%: 10 key notes
Boston Scientific, Brainlab enter strategic collaboration — 5 key takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
